Did anyone else pick up on the rumor a few weeks ago that Sanofi-Aventi might be interested in acquiring Allergan? I assumed that was what caused the pop in the stock. The latest on Sanofi's target with no mention of Allergan might be what's deflated the price.
The bump was initiated by the SNY buy-out rumour, although anyone familiar with both companies would know that AGN is not a viable canidate for SNY. SNY wants to spend less than $15 Billion, and Allergan has already been said to turn down bids above the $20 billion range by other suitors in the last year.